Author

Laura Sánchez

Instituto de Salud Carlos III

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adele Chloe Cardeñosa Pérez· 1 shared Aleksi Pekkarinen· 1 shared Alexander Thomas BaueriD· 1 shared Alexandra CortegosoiD· 1 shared ALFONSO L. CALLE· 1 shared Alicia AbaloiD· 1 shared Alicia JuradoiD· 1 shared Ana Belén Dávila-IbáñeziD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPathology

Adele Chloe Cardeñosa Pérez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PathologybioRxivPreprintSep 18, 2025

Intermittent Hypoxia Drives Early Metabolic Dysfunction in Brown Adipose Tissue

Nuria Pescador, Maria Fernandez-Canizares, Yosra Berrouayel…·Luis del Peso

This study shows intermittent hypoxia impairs brown adipose tissue function through molecular and morphological changes, preceding systemic metabolic dysfunction in mice.

DOI 10.1101/2025.09.18.676807

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Experimental & Clinical Cancer ResearchPeer-reviewedApr 29, 2025

Red blood cell-tumour cell interactions promote tumour cell progression

Thais Pereira‐Veiga, Celso Yáñez-Gómez, Aleksi Pekkarinen…·Clotilde Costa

This study shows that red blood cells from cancer patients enhance tumour cell invasiveness and metastatic potential through gene and protein changes, suggesting PAK4 as a therapeutic target.

10 citationstop 5%

humanbulk RNA-seq

𝕏 PostBluesky